Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

References

• Christman J K, Mendelsohn N, Herzog D, Schneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res 1983; 43: 763–769
   PubMed Web of Science ®Google Scholar
• Creusot F, Acs G, Christman J K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 1982; 257: 2041–2048
   PubMed Web of Science ®Google Scholar
• Leone G, Teofili L, Voso M T, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87: 1324–1341
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Clark S J, Harrison J, Paul C L, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22: 2990–2997
   PubMed Web of Science ®Google Scholar
• Colella S, Shen L, Baggerly K A, Issa J P, Krahe R. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35: 146–150
   PubMed Web of Science ®Google Scholar
• Cheson B D, Greenberg P L, Bennett J M, Lowenberg B, Wijermans P W, Nimer S D, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kantarjian H, Pinto A, Schiffer C A, Nimer S D, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kopecky K J, Buchner T, Willman C L, Estey E H, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa J P, Rosenfeld C S, Bennett J M, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803
   PubMed Web of Science ®Google Scholar
• Silverman L R, Demakos E P, Peterson B L, Kornblith A B, Holland J C, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57
   PubMed Web of Science ®Google Scholar
• Silverman L R, McKenzie D R, Peterson B L, Holland J F, Backstrom J T, Beach C L, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895–3903
   PubMed Web of Science ®Google Scholar
• Yang A S, Estecio M R, Doshi K, Kondo Y, Tajara E H, Issa J P. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32: e38
   PubMed Web of Science ®Google Scholar
• Yang A S, Doshi K D, Choi S W, Mason J B, Mannari R K, Gharybian V, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495–5503
   PubMed Web of Science ®Google Scholar
• Oki Y, Kantarjian H, Davis J, Ravandi F, Verstovsek S, Cortes J. Hypomethylation induction in MDS after treatment with decitabine at three different doses. J Clin Oncol 2005, 16S[abstr 6546]
   Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Cortes J, Giles F J, Faderl S, Issa J P, et al. Results of decitabine (5-aza-2′-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98: 522–528
   PubMed Web of Science ®Google Scholar
• Issa J P, Garcia-Manero G, Giles F J, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635–1640
   PubMed Web of Science ®Google Scholar